WO2008143782A1 - Conservation de substances biologiquement actives par mousse lyophilisée - Google Patents

Conservation de substances biologiquement actives par mousse lyophilisée Download PDF

Info

Publication number
WO2008143782A1
WO2008143782A1 PCT/US2008/005840 US2008005840W WO2008143782A1 WO 2008143782 A1 WO2008143782 A1 WO 2008143782A1 US 2008005840 W US2008005840 W US 2008005840W WO 2008143782 A1 WO2008143782 A1 WO 2008143782A1
Authority
WO
WIPO (PCT)
Prior art keywords
foam
formulation
less
drying
temperature
Prior art date
Application number
PCT/US2008/005840
Other languages
English (en)
Inventor
Reinhard Vehring
Yi Ao
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Priority to DK08767620.1T priority Critical patent/DK2148923T3/da
Priority to US12/451,454 priority patent/US8617576B2/en
Priority to JP2010509335A priority patent/JP5307801B2/ja
Priority to BRPI0811161-8A2A priority patent/BRPI0811161A2/pt
Priority to ES08767620T priority patent/ES2393160T3/es
Priority to CN200880025155.3A priority patent/CN101755044B/zh
Priority to EP08767620A priority patent/EP2148923B1/fr
Publication of WO2008143782A1 publication Critical patent/WO2008143782A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/34—Processes using foam culture

Definitions

  • the present invention is in the field of preservation of biologic materials in storage.
  • the invention relates to, e.g., preservation of bioactive molecules and viable biologies by glassification in a protective dry foam matrix. Processes and systems provide high recovery of virus and bacteria viability.
  • Biological materials such as proteins, eukaryotic cells, bacteria and viruses, are generally unstable when stored in media or other liquid solutions.
  • enveloped viruses such as live Influenza virus manufactured from egg allantoid fluid loose one log of potency, defined as Tissue Culture Infectious Dose (TCID 5 o), in less than two to three weeks when stored under refrigerated temperature, i.e. approximately 4°C. At room temperature conditions (approximately 25°C) and at warmer temperatures such as 37°C, the virus looses such potency in a matter of days to hours, respectively. Lyophilization processes, where aqueous formulas are frozen and then dried by sublimation, are commonly used to stabilize these biological materials.
  • Protective agents are chemicals that are added to a formulation to protect cells and molecules during freezing and to enhance stability during storage.
  • stabilizers for live virus vaccines generally include high concentrations of sugars such as sucrose, mannitol, or sorbitol to improve virus stability during lyophilization and storage.
  • sugars such as sucrose, mannitol, or sorbitol
  • the protective agents may not penetrate adequately to protect active molecules within the membrane volume. Therefore, a significant challenge remains to develop an optimal drying process and formulation to achieve adequate stability for labile biologies.
  • Dry foam preservation processes of this type have the advantage of faster drying due to convection of the liquid during boiling and the increased surface area presented by the foam bubble surfaces.
  • the hot secondary drying to low moisture levels can reduce cell and virus viability by 90% or more.
  • Reconstitution of such a dry foam can be rapid due to the presence of the hydrophilic protective agents and the large foam surface area.
  • the dry foam can be milled to a fine powder to further improve reconstitution times or for administration of the biological material by inhalation.
  • the dry foam preservation processes described above are limited in their flexibility to protect a variety of biological materials.
  • the process rules out a freezing step (e.g., see Bronstein at column 1, line 41 - "[f]reezing and other steps of the freeze-drying process are very damaging to many sensitive biological materials.") and subsequent sublimation of the ice as a means to remove water from the foam.
  • freezing is avoided in Bronshtein, the formulation must be thickened before foaming and drying so that large amounts of water are not lost, along with latent heat, to freeze the foam.
  • the avoidance of freezing requires the process to be conducted at lower vacuum level (7-24 Torr) than in conventional freeze drying or spray freeze drying process cycles. Boiling in Bronshtein, requires input of significant, and possibly destabilizing, amounts of heat to provide the necessary eruption of foam.
  • the Bronshtein dry foam process is not particularly well adapted to preservation of biological materials having lipid membranes.
  • the process is not well adapted to preservation of biologicals, such as liposomes, viruses or viable cells.
  • Lipid membranes often prevent penetration of the protective agents into enclosed volumes or prevent adequate removal of water from the enclosed volume. Without adequate penetration of protective agents, enzymatic processes, such as proteolysis, and chemical processes, such as oxidation and free radical attacks, can destroy the activity or viability of the biological material. Hypoosmotic fluids remaining within membrane enclosed volumes can promote instability of the biological material. Hot secondary drying can kill cells.
  • the present invention includes methods, systems and compositions for preserving bioactive materials, such as peptides, proteins, nucleic acids, antibodies, vaccines, bacteria, viruses, liposomes, platelets, and/or cell suspensions, in storage.
  • the methods generally provide, e.g., processes of expanding a formulation of the bioactive material and a polyol into a foam, freezing the foam, and drying the foam into a stable dry foam composition.
  • the methods can variously include, e.g., freezing of the foam before drying, inclusion of foaming agents in the formulation, holding the formulation at the phase transition temperature of a lipid membrane to enhance penetration of protective agents, expansion of the formulation at pressures between about 200 Torr and 25 mTorr, secondary drying of the foam in the form of a thin layer, and/or drying the foam at a relatively low temperature, such as room temperature or less.
  • the methods of the invention typically include providing a bioactive material e.g., a peptide, protein, nucleic acid, antibodies, vaccines, bacteria, viruses, liposomes, platelets, and/or cell suspensions, in a formulation including a polyol, expanding the formulation into a foam, freezing the foam, drying by lyophilization, and removing residual moisture at a low temperature.
  • a bioactive material e.g., a peptide, protein, nucleic acid, antibodies, vaccines, bacteria, viruses, liposomes, platelets, and/or cell suspensions
  • a method for preparing a stable dry foam composition of a bioactive material can include the steps of: preparing a formulation comprising the bioactive material, and a polyol or polymer, in a solvent (e.g., water); expanding the formulation into a foam; freezing the foam; primary drying the foam by evaporation or sublimation at a foam temperature of 0 0 C or less; and, secondary drying the foam in an environment with a temperature of 25°C or less for a time sufficient to reduce the foam to a residual moisture of 10 percent or less.
  • a solvent e.g., water
  • a formulation comprising the bioactive material, and a polyol or polymer, in a solvent is prepared; the formulation is expanded into a foam; the foam is frozen; the foam is dried by evaporation or sublimation at a temperature wherein the foam is frozen and remains below the glass transition temperature of the foam; and, the foam is secondarily dried in an environment of 25°C or less for a time sufficient to reduce the foam to a 10 percent residual moisture or less.
  • bioactive materials comprising volumes enclosed in a lipid membrane, it can be preferred to hold the formulation or foam at a temperature within 2°C of a membrane transition temperature of the bioactive material for 2 or more minutes before expanding the foam.
  • the bioactive material comprises peptides, proteins, nucleic acids, antibodies, vaccines, bacteria, viruses, liposomes, platelets, and/or cell suspensions.
  • the bioactive material comprises a virus or bacteria, e.g., a Listeria bacterium or Influenza strain.
  • the Listeria is Listeria monocytogenes.
  • an attenuated strain of Listeria monocytogenes is used.
  • a strain of Listeria monocytogenes recombinantly engineered as a vaccine to express an antigenic peptide is used. Construction of Listeria-based vaccines, including accessory sequences, is provided in detail in U.S.
  • the Influenza strains are Influenza A and B viruses.
  • the Influenza strains are attenuated for use as a live vaccine.
  • the foam comprises a thickness of 2 mm or less, e.g., to expedite secondary drying at low temperatures of, e.g., 25°C or less, 20 0 C or less, 15°C or less. It is preferred for stability of the final product that the foam is dried for a time sufficient to reduce the foam to a residual moisture of 10 percent or less, 5 percent or less, 3 percent or less or 1 percent or less. It is often preferable that the secondary drying temperature remains below the glass transition temperature of the foam polyol matrix.
  • the primary drying and/or secondary drying comprise removal of solvents at a pressure of 100 Torr or less, 50 Torr or less, 10 Torr or less, 1 Torr 100 mTorr, 10 mTorr, or less, e.g., to speed removal of moisture from the foam at low temperatures.
  • the dried foam can be in the form of sheets or large particles.
  • the dried foam can be ground into a powder with an average particle size from, e.g., about 0.1 um to about 100 um, for storage or for administration by inhalation.
  • the foam can be administrated to a mammal as a reconstituted liquid, e.g., by injection.
  • the present invention includes systems to effectively practice the methods of preparing stable dry foam compositions.
  • systems that allow quick secondary drying at relatively low temperatures, such as 20 0 C or less can openly expose the foam to a strong vacuum in the form of a thin sheet.
  • a system for preparing a stable dry foam composition of bioactive material can include an environment control chamber providing control of internal temperatures and internal pressures; and, a foam within the chamber comprising a bioactive material, and a polyol or polymer, in a solvent. Drying can be accelerated by providing the foam with a thickness of 2 mm or less and/or an aspect ratio (width or length to thickness) of 10 or more; or a thickness of 1 mm or less and/or an aspect ratio of 100 or more.
  • the foam is preferably dried to a 10 percent residual moisture or less, at a temperature of 25°C or less, over a time period of 2 days or less.
  • the bioactive material of the systems can be any bioactive material.
  • the systems present known benefits particularly to viability of viruses or bacteria, e.g., Listeria bacterium or Influenza strains.
  • the Listeria is Listeria monocytogenes.
  • an attenuated strain of Listeria monocytogenes is used.
  • a strain of Listeria monocytogenes recombinantly engineered as a vaccine to express an antigenic peptide is used.
  • the Influenza strains are Influenza A and B viruses.
  • the Influenza strains are attenuated for use as a live vaccine.
  • the present invention includes stable dry foam compositions.
  • the compositions can include: peptides, proteins, nucleic acids, antibodies, vaccines, bacteria, viruses, liposomes, platelets, and/or cell suspensions, in a dry foam matrix comprising a 10 percent residual moisture or less, wherein the matrix comprises a polyol and/or polymer, and wherein the dry foam was prepared from a liquid formulation of the bioactive material with less than a 0.5 log ⁇ loss of viability.
  • the bioactive materials of virus or bacterium can include, e.g., a Listeria bacterium or Influenza strain.
  • the Listeria is Listeria monocytogenes.
  • an attenuated strain of Listeria monocytogenes is used.
  • a strain of Listeria monocytogenes recombinantly engineered as a vaccine to express an antigenic peptide is used, e.g., which peptide is not a native Listeria peptide.
  • the Influenza strains are Influenza A and B viruses.
  • the Influenza strains are attenuated for use as a live vaccine.
  • the virus or bacterium can include, e.g., a Listeria bacterium or Influenza strain.
  • the process loss of viability is less than a 0.5 log 10 loss, less than a 0.3 log t o loss, less than a 0.1 1Og 1O loss, e.g., accomplished using the methods and/or systems of the present invention.
  • Ambient temperatures or conditions are those at any given time in a given environment. Typically, ambient room temperature is 22°C, ambient atmospheric pressure, and ambient humidity are readily measured and will vary depending on the time of year, weather conditions, altitude, etc.
  • Boiling refers, e.g., to the rapid phase transition from liquid to gas that takes place when the temperature of a liquid is above its boiling temperature. The boiling temperature, as is well known to those skilled in the art, is the temperature at which the vapor pressure of a liquid is equal to the applied pressure. Boiling can be particularly vigorous when heat is added to a liquid that is at its boiling point.
  • Buffer refers to a buffered solution that resists changes in pH by the action of its acid-base conjugate components.
  • the pH of the buffer will generally be chosen to stabilize the active material of choice, and will be ascertainable by those in the art. Generally, this will be in the range of physiological pH, although some proteins, can be stable at a wider range of pHs, for example acidic pH. Thus, preferred pH ranges are from about 1 to about 10, with from about 3 to about 8 being particularly preferred; more preferably, from about 6.0 to about 8.0; yet more preferably, from about 7.0 to about 7.4; and most preferably, at about 7.0 to about 7.2.
  • Suitable buffers include a pH 7.2 phosphate buffer and a pH 7.0 citrate buffer.
  • Suitable buffers include, but are not limited to, potassium phosphate, sodium phosphate, sodium acetate, histidine, imidazole, sodium citrate, sodium succinate, ammonium bicarbonate and carbonate.
  • buffers are used at molarities from about 1 mM to about 2 M, with from about 2 mM to about 1 M being preferred, and from about 10 mM to about 0.5 M being especially preferred, and 25 to 50 mM being particularly preferred.
  • Degassing refers to the release of a gas from solution in a liquid when the partial pressure of the gas is greater than the applied pressure. If water is exposed to nitrogen gas at one atmosphere (about 760 Torr), and the partial pressure of nitrogen in the water equilibrates to the gas phase pressure, nitrogen can bubble from the water if the gas pressure is reduced. This is not boiling, and can often occur at pressures above a pressure that would boil a solvent. For example, bottled carbonated soft drinks, with a high partial pressure of CO 2 gas, bubble rapidly (but do not boil) when pressure is reduced by removing the bottle cap.
  • Dispersibility means the degree to which a powder composition can be dispersed (i.e. suspended) in a current of air so that the dispersed particles can be respired or inhaled into the lungs of a subject. Thus, a powder that is only 20% dispersible means that only 20% of the mass of particles can be suspended for inhalation into the lungs.
  • “Dry”, in the context of dried foam compositions refers to residual moisture content less than about 10%. Dried foam compositions are commonly dried to residual moistures of 5% or less, or between about 3% and 0.1%.
  • a "dry foam” can be a stabilized foam with less than 10% residual moisture content, a foam after primary drying, and/or a foam after secondary drying.
  • “Dry” in the context of particles for inhalation means that the composition has a moisture content such that the particles are readily dispersible in an inhalation device to form an aerosol.
  • Primary drying refers to the drying that takes place from the time of initial freezing of the foam to the point where secondary drying starts. Typically, the bulk of primary drying takes place by sublimation at freezing temperatures.
  • Secondary drying refers to drying that takes place at temperatures above freezing temperatures (e.g., 0 0 C or the freezing point of the frozen formulation). In a typical freeze- foam drying process, a secondary drying step takes the foam from a residual moisture of about 25 percent to a 10 percent residual moisture value or less.
  • Excipients or “protectants” (including cryoprotectants and lyoprotectants) generally refer to compounds or materials that are added to ensure or increase the stability of the therapeutic agent during the spray freeze dry process and afterwards, for long term stability and flowability of the powder product. Suitable excipients are generally relatively free flowing particulate solids, do not thicken or polymerize upon contact with water, are basically innocuous when inhaled by a patient and do not significantly interact with the therapeutic agent in a manner that alters its biological activity.
  • Suitable excipients include, but are not limited to, proteins such as human and bovine serum albumin, gelatin, immunoglobulins, carbohydrates including monosaccharides (galactose, D-mannose, sorbose, etc.), disaccharides (lactose, trehalose, sucrose, etc.), cyclodextrins, and polysaccharides (raffinose, maltodextrins, dextrans, etc.); an amino acid such as monosodium glutamate, glycine, alanine, arginine or histidine, as well as hydrophobic amino acids (tryptophan, tyrosine, leucine, phenylalanine, etc.); a methylamine such as betaine; an excipient salt such as magnesium sulfate; a polyol such as trihydric or higher sugar alcohols, e.g.
  • proteins such as human and bovine serum albumin, gelatin, immunoglobulins, carbohydrates
  • glycerin erythritol, glycerol, arabitol, xylitol, sorbitol, and mannitol
  • propylene glycol polyethylene glycol
  • Pluronics surfactants; and combinations thereof.
  • Glass or “glassy state” or “glassy matrix,” refers to a liquid that has lost its ability to flow, i.e. it is a liquid with a very high viscosity, wherein the viscosity ranges from 10 10 to 10 14 pascal-seconds. It can be viewed as a metastable amorphous system in which the molecules have vibrational motion but have very slow (almost immeasurable) rotational and translational components. As a metastable system, it is stable for long periods of time when stored well below the glass transition temperature. Because glasses are not in a state of thermodynamic equilibrium, glasses stored at temperatures at or near the glass transition temperature relax to equilibrium and lose their high viscosity.
  • freeze foams of the invention include, e.g., a foamed open cell and/or closed cell macro structure not found in prior art freeze dried materials.
  • the process used to obtain a glassy matrix for the purposes of this invention is generally a solvent sublimation and/or evaporation technique.
  • the "glass transition temperature” is represented by the symbol T g and is the temperature at which a composition changes from a glassy or vitreous state to a syrup or rubbery state.
  • T g is determined using differential scanning calorimetry (DSC) and is standardly taken as the temperature at which onset of the change of heat capacity (Cp) of the composition occurs upon scanning through the transition.
  • DSC differential scanning calorimetry
  • Cp change of heat capacity
  • the definition of T g is always arbitrary and there is no present international convention.
  • the T g can be defined as the onset, midpoint or endpoint of the transition; for purposes of this invention we will use the onset of the changes in Cp when using DSC. See the article entitled "Formation of Glasses from Liquids and Biopolymers" by C. A.
  • Porture enhancers are surface active compounds that promote penetration of a drug through a mucosal membrane or lining and can be generally used where this feature is desirable, e.g., intranasally, intrarectally, and intravaginally.
  • “Pharmaceutically acceptable” excipients are those which can reasonably be administered to a subject mammal to provide an effective dose of the active ingredient employed.
  • these are excipients which the Federal Drug Administration (FDA) have to date designated as 'Generally Regarded as Safe' (GRAS).
  • FDA Federal Drug Administration
  • GRAS 'Generally Regarded as Safe'
  • “Pharmaceutical composition” refers to preparations which are in such a form as to permit the biological activity of the active ingredients to be unequivocally effective, and which contain no additional components which are toxic to the subjects to which the composition would be administered.
  • a "polyol” is an organic substance with multiple hydroxyl groups, and includes, e.g., sugars (reducing and nonreducing sugars), sugar alcohols and sugar acids. Preferred polyols herein have a molecular weight which is less than about 600 kDa (e.g. in the range from about 120 to about 400 kDa).
  • a "reducing sugar” is a polyol which contains a hemiacetal group that can reduce metal ions or react covalently with lysine and other amino groups in proteins.
  • a “nonreducing sugar” is a sugar which does not have these properties of a reducing sugar.
  • reducing sugars are fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose and glucose.
  • Nonreducing sugars include sucrose, trehalose, sorbose, melezitose and raffinose.
  • Mannitol, xylitol, erythritol, threitol, sorbitol and glycerol are examples of sugar alcohols.
  • sugar acids these include L-gluconate and metallic salts thereof.
  • a "Powder” is a composition that consists of finely dispersed solid particles that are relatively free flowing and capable of being readily dispersed in an inhalation device and subsequently inhaled by a patient so that the particles are suitable for intranasal or pulmonary administration via the upper respiratory tract including the nasal mucosa.
  • T s at which powdered drug composition can be stored to maintain the stability of the drug product over the shelf life of the composition in order to ensure a consistently delivered dose.
  • This temperature is initially determined by the manufacturer of the composition and approved by the governmental agency responsible for approval the composition for marketing (e.g., the Food and Drug Administration in the U.S.). This temperature will vary for each approved drug product depending on the temperature sensitivity of the active drug and other materials in the product.
  • the recommended storage temperature will vary from about 0° to about 40°C, but generally will be ambient temperature, i.e. about 25°C. Usually a drug product will be kept at a temperature that is at or below the recommended storage temperature.
  • a biologically active material "retains its biological activity" in a pharmaceutical composition, if the biological activity of the biologically active material, such as an enzyme, at a given time is within about 10% (within the errors of the assay) of the biological activity exhibited at the time the pharmaceutical composition was prepared as determined in a binding assay, for example.
  • biological activity can be considered retained when the viral titer or colony count of the composition is within one log of the initial titer or count.
  • live cells the biological activity is considered retained when the live cell count of the composition is within 50% of the initial count.
  • the assay that is used to determine live influenza virus titer is the Fluorescent Focus Assay (FFA assay).
  • log FFU/ml log Fluorescent Focus Unit per milliliter
  • log TCID 5 o/ml log Tissue Culture Infectious Dose per ml
  • a biologically active material "retains its chemical stability" in a pharmaceutical composition, if the chemical stability at a given time is such that the biologically active material is considered to retain its biological activity as defined herein.
  • Chemical stability can be assessed by detecting and quantifying chemically altered forms of the biologically active material.
  • Chemical alteration may involve size modification (e.g. clipping of proteins), which can be evaluated using size exclusion chromatography, SDS- PAGE and/or matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI/TOF MS), for example.
  • Other types of chemical alteration include charge alteration (e.g. occurring as a result of deamidation), which can be evaluated by ion- exchange chromatography, for example.
  • a biologically active material "retains its physical stability" in a pharmaceutical composition if it shows no significant increases in aggregation, precipitation and/or denaturation upon visual examination of color and/or clarity, or as measured by UV light scattering or by size exclusion chromatography.
  • a “stable" formulation or composition is one in which the biologically active material therein essentially retains its physical stability and/or chemical stability and/or biological activity upon storage.
  • Various analytical techniques for measuring stability are available in the art and are reviewed, e.g., in Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, N. Y., Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10: 29-90 (1993). Stability can be measured at a selected temperature for a selected time period. Trend analysis can be used to estimate an expected shelf life before a material has actually been in storage for that time period.
  • stability is defined as the time it takes to loose 1 log of FFU/ml or 1 log of TC ⁇ D 5 o/ml.
  • the composition is stable at room temperature ( ⁇ 25°C) for at least three months, or at 40°C for at least 1 month, and/or stable at about 2-8°C for at least 1 year.
  • the composition is preferably stable following freezing (to, e.g., -70°C) and thawing of the composition.
  • a "therapeutically effective amount" of a biologically active material refers to an amount effective in the prevention or treatment of a disorder wherein a “disorder” is any condition that would benefit from treatment with the biologically active material. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
  • Treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
  • Unit dosage refers to a receptacle containing a therapeutically effective amount of a composition of the invention.
  • Viability refers to the ability to form a colony on a nutrient media appropriate for the growth of the bacteria. Viability, with regard to viruses, refers to the ability to infect and reproduce in a suitable host cell, e.g., resulting in the formation of a plaque on a lawn of host cells.
  • Figure 1 is a chart of temperature and pressure versus time during an exemplary foam drying process.
  • Figure 2A to 2D are photographic images of a formulation freeze foam drying in glass vials.
  • Figure 3 shows the phase transitions of FluMistTM A/Sydney Influenza virus vaccine using Fourier transformed infrared spectroscopy (FTIR).
  • Figure 4 shows process activity (viral titer) loss for B/Harbin influenza virus vaccine after the freeze dry foaming process where drying was conducted at 1O 0 C, 15 0 C, and 2O 0 C.
  • Figure 5 shows the stability trend of B/Harbin influenza virus vaccine which was subjected to the freeze dry foaming process where primary drying was conducted at 1O 0 C, 15 0 C, or 2O 0 C.
  • Figure 6 shows the stability trend for potency of foam dried B/Ann Arbor influenza virus in storage at 37 0 C and 5O 0 C.
  • Figure 7 shows the stability trends for three different strains of influenza virus vaccine foam dried in formulation AVS53.
  • Figure 8 shows X-ray diffraction data and an electron micrograph demonstrating the amorphous nature of a foam composition of the invention.
  • Figure 9 shows a chart of process temperatures and cumulative viability loss for a freeze-foam process ending with a 33°C secondary drying step.
  • Figure 10 shows a chart of Listeria viability as water is removed in a freeze foam process. Secondary drying at a lower temperature provided 10-fold better viability in a dry foam having less than 5 percent residual moisture than for the same material secondarily dried at a higher temperature.
  • Figure 11 is a schematic diagram of an exemplary system for low temperature freeze-foam drying.
  • Figures 12A and B present charts showing the benefits to microbe viability with low temperature secondary drying as compared to moderate temperature drying.
  • Figure 13 presents a chart showing how stepped secondary drying temperatures can reduce final moisture levels while increasing viability as compared to non- stepped processes.
  • Figure 14 presents a chart showing evidence that viability in microbe freeze foam drying is not substantially affected by whether or not the foam matrix experiences a non-glass condition.
  • the methods and compositions of the present invention can provide extended storage of bioactive materials, such as, e.g., peptides, proteins, nucleic acids, antibodies, vaccines, bacteria, viruses, liposomes, platelets, and/or cell suspensions, in a glassy matrix of a dry foam.
  • Methods of the invention provide a dry foam preservative composition by, e.g., preparing a formulation comprising a bioactive material with a polyol or polymer in a solvent (with or without a foaming agent), reducing pressure to expand the formulation into a foam (by degassing, boiling, and/or expansion of introduced bubbles), and stabilizing the foam by evaporating or sublimating the solvent from the foam (with or without freezing the foam).
  • the bioactive material can be formulated into a suspension with protective agents, precooled, held at a temperature near the phase transition temperature of the membrane to allow the protective agents to penetrate the membrane before expanding the formulation into a foam, dried in a thin foam layer, dried at very low pressures, and dried at a low secondary drying temperature, e.g., near room temperature.
  • Methods for preparing stable dry foams for preservation of bioactive materials includes, in general, e.g., preparation of a formulation combining the bioactive material with a polyol and/or polymer in a solution or suspension, reducing the pressure applied to the formulation to initiate foaming, freezing the foam, primary drying of the foam by lyophilization, and secondary drying of the foam to 10 percent residual moisture or less at a temperature of about 25°C or less.
  • the foam drying process includes, e.g., holding a formulation of microorganism and a polyol at a temperature about the phase transition temperature of the microorganism membranes.
  • the formulation is chilled to within 10°C of freezing before expanding the formulation into a foam by reduction or the atmospheric pressure below ambient pressure conditions. Loss of latent heat and/or environmental chilling freeze the foam.
  • the foam experiences preliminary drying by lyophilization to about 60% or 75% solids, or more. Secondary drying is performed in an environment with a temperature above freezing. During the all or most of the secondary drying phase, it can be preferred that the foam remains frozen and/or below the glass transition temperature (Tg) of the foam. Secondary drying is typically complete when residual moisture has been reduced to about 10 percent or less; preferably, about 5 percent moisture.
  • a formulation of bioactive material, polyol and/or polymer, in a solvent is expanded to a foam under a pressure of between about 200 Torr and about 25 Torr before stabilizing and drying the foam.
  • This embodiment is distinguished from prior art discussed above, e.g., in not requiring a strong vacuum (pressure 24 Torr or less) in order to obtain adequate foam expansion.
  • adequate foaming can be obtained at higher pressures because the methods of the invention provide foam expansion, e.g., from degassing of saturated gasses from the formulation, boiling of high vapor pressure solvents from the formulation, gas forming chemistries, and/or enlargement of bubbles injected or trapped in the formulation.
  • Formulations of this embodiment can be, e.g., precooled and/or lose substantial latent heat during expansion of foam or drying to, e.g., optionally result in freezing and/or lyophilization of the foam.
  • the stabilized dry foam can be held, e.g., at secondary drying temperatures at pressures below 50 mTorr, to complete drying of the formulation.
  • a foaming agent is present in the formulation, e.g., to provide foam expansion and/or control with or without boiling.
  • a formulation containing a foaming agent, a bioactive material, and a polyol and/or polymer can be subjected to a reduced pressure in which the formulation is expanded into a foam (by action of the foaming agent), stabilized and dried.
  • the foaming agent can be, e.g., gas in solution in the formulation, a high vapor pressure (volatile) solvent, a carbonate, an active metal, a direct electric current, a suspension of fine gas bubbles, and/or the like, as described below in the Foaming the Formulation section.
  • Another embodiment of the invention provides, e.g., methods to prepare lyophilized foam compositions for preservation of bioactive materials.
  • a formulation containing a bioactive material, and a polyol and/or polymer can be expanded into a foam under reduced pressure, frozen and sublimated to provide a lyophilized dry foam composition.
  • Freezing in this embodiment, can be, e.g., by conduction of heat away from the formulation, and/or by loss of latent heat due to solvent evaporation or sublimation.
  • the present invention includes, e.g., methods for preservation of biological materials having a lipid membrane component.
  • Methods for preserving bioactive materials comprising lipid membranes can include, e.g., cooling a biologic material formulation to a membrane phase transition temperature of about 45°C to 0°C for about 30 minutes in a solution containing about 2% to 40% of a polyol protective agent.
  • the protective agents can, e.g., penetrate the membranes in phase transition to stabilize biological molecules within enclosed volumes.
  • a membrane phase transition temperature is the temperature at which the lipid membrane transitions between a fluid (high mobility) phase to a more rigid gel-crystalline phase.
  • lipid membranes tend to be pervious to passive diffusion of external milieu at lipid bilayer's characteristic phase transition temperature, one way to load stabilizers/protective agents to the cells, bacteria, or viruses is by preincubating at such phase transition.
  • Pressure can then be reduced, e.g., to boil the formulation and produce a foam.
  • Water can be rapidly lost from the formulation, along with latent heat, resulting, e.g., in freezing of the foam. Water continues to be lost, e.g., by sublimation over the course of several minutes to provide a substantially dry foam composition.
  • the temperature can be warmed, e.g., to drive off additional residual moisture and water of hydration to enhance the physical and/or chemical stability of the dry foam.
  • Figure 1 shows an exemplary freeze foam drying process of the invention.
  • Chamber temperature line 11 indicates the temperature of the vacuum chamber during the freeze foaming process.
  • the chamber temperature is held at about the phase transition temperature of the virus, or about 15°C, through penetration stage 12, foaming stage 13, and initial (primary) drying stage 14.
  • the chamber temperature was ramped up to drying temperatures of about 33°C during secondary drying phase 15.
  • Chamber pressure line 16 remains at or above atmospheric pressure during the penetration stage, drops to about 2500 mTorr during the foaming stage, about 250 mTorr during the initial drying stage, and about 50 mTorr during the secondary drying stage.
  • Vial temperature lines 17 represent temperatures measured from thermocouples placed into formulations in representative vials during the process.
  • the vials hold the membrane phase transition temperature during the penetration stage but chill suddenly as the pressure drops during the foaming stage due to loss of latent heat from evaporation and sublimation of water from the formulation.
  • Vial temperatures gradually rise to near chamber drying temperatures as the rate of residual moisture loss tapers off in the secondary drying stage.
  • Figures 2A to 2D show photographic images of representative vials of formulation during stages of freeze foam drying.
  • liquid formulation at the bottom of the vial is beginning to boil as pressure in the chamber begins to drop.
  • a foamy matrix has begun to stabilize as it thickens with loss of water and lower temperatures.
  • Figure 2C the foam is frozen and has lost most of the initial drying stage water.
  • Figure 2D shows the dried foam glassy matrix well into the secondary drying stage.
  • the formulation includes a live attenuated influenza virus bioactive material in a solution of 40% sucrose, 5% gelatin, 0.02% Pluronic F68, and a pH 7.2 phosphate buffer.
  • the formulation is aliquoted into sterile 10 ml siliconized glass vials and precooled to 15°C (about the phase transition temperature of the virus envelope, see Figure 3) for about 30 minutes.
  • the pressure is rapidly reduced to about 50 mTorr for about an half an hour to generate the foam with ice nucleation and ice propagation throughout. After the initial foaming and freezing, ice sublimation and evaporation produce a physically stable foam.
  • a foam can be generated at vacuums between about 400 Torr and 7.7 Torr or less, or 2.5 Torr to about 50 mTorr, when the formulation contains foaming agents).
  • the temperature is increased to about 33°C for about 2 days in a secondary drying step to reduce the residual moisture of the composition to a desired level.
  • the vials are aseptically sealed to keep out contaminants and moisture for stability in storage.
  • Formulations of the invention can include, e.g., a bioactive material formulated into a solution or suspension containing a polyol, polymer, foaming agent, surfactant, and/or a buffer.
  • the formulation ingredients can be combined in a sequence using techniques appropriate to the constituents, as is appreciated by those skilled in the art.
  • the polymers and/or high concentrations of polyols can be dissolved into a heated aqueous solution with agitation before cooling and admixture with the bioactive material.
  • the bioactive material such as a virus or bacterium, can be, e.g., concentrated and separated from growth media by centrifugation or filtration before resuspension into the formulation.
  • the bioactive material can be, e.g., a material of interest that provides any bioactivity, such as, e.g., enzymatic activity, storage of genetic information, an affinity interaction, induction of immune responses, cellular multiplication, infection, inhibition of cell growth, stimulation of cell growth, therapeutic effects, pharmacologic effects, antimicrobial effects, and/or the like.
  • the bioactive materials can be, enzymes, antibodies, hormones, nucleic acids, bacteria, viruses, liposomes, platelets, other cells, and/or the like.
  • the bioactive material can be, e.g., living cells and/or viable viruses.
  • the bioactive material can be, e.g., nonliving cells or liposomes useful as vaccines or delivery vehicles for therapeutic agents.
  • Viral bioactive materials of the invention can be, e.g., live viruses and live attenuated viruses such as, influenza virus, parainfluenza virus, AAV, adenovirus, respiratory syncytial virus, herpes simplex virus, cytomegalovirus, SARS virus, corona virus family members, human metapneumovirus, Epstein-Barr virus, and/or the like.
  • live viruses and live attenuated viruses such as, influenza virus, parainfluenza virus, AAV, adenovirus, respiratory syncytial virus, herpes simplex virus, cytomegalovirus, SARS virus, corona virus family members, human metapneumovirus, Epstein-Barr virus, and/or the like.
  • the protective agents of the methods can include, e.g., any of a variety of polyols.
  • the polyol such as sucrose
  • the polyol can physically surround the bioactive material to promote retention of molecular structure throughout the drying process and impart structural rigidity to the glassy matrix in the dry state.
  • Other functions of the polyol can include, e.g., protecting the bioactive material from exposure to damaging light, oxygen, moisture, and/or the like.
  • the polyol, such as sucrose can physically surround and protect the bioactive material from exposure to damaging light, oxygen, moisture, and/or the like.
  • the polyols can, e.g., replace water of hydration lost during drying, to prevent denaturation of biomolecules of the material.
  • polyols can provide, e.g., a thickener with tenacity to foster formation and stabilization of bubbles that form the dry foam structure of the preservative compositions.
  • the formulation and foam compositions can include, e.g., sucrose, trehalose, sorbose, melezitose, sorbitol, stachyose, raffinose, fructose, mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose, glucose, mannitol, xylitol, erythritol, threitol, sorbitol, glycerol, L-gluconate, and/or the like.
  • Most polyols can be readily dissolved for mixture into the formulation in amounts ranging, e.g., from about 1 weight percent to about 45 weight percent
  • Polymers can be included in the formulations of the method, e.g., to provide protective benefits and/or foam structural stability.
  • polymers can provide, e.g., physical and chemical protection to the bioactive materials.
  • the polymers can often provide, e.g., more thickening viscosity by weight to the formulation than simple polyols.
  • the linear or branching strands of polymers can provide, e.g., increased structural strength to the dried foam compositions of the invention.
  • Many polymers are, e.g., highly soluble in water, so they do not significantly hinder reconstitution of dry foams.
  • Polymer protective agents in the methods of the invention can include, e.g., hydrolyzed gelatin, unhydrolyzed gelatin, water soluble polymers such as polyvinyl pyrrolidone, ovalbumin, collagen, chondroitin sulfate, a sialated polysaccharide, actin, myosin, microtubules, dynein, kinetin, human serum albumin, and/or the like.
  • water soluble polymers such as polyvinyl pyrrolidone, ovalbumin, collagen, chondroitin sulfate, a sialated polysaccharide, actin, myosin, microtubules, dynein, kinetin, human serum albumin, and/or the like.
  • Foaming agents can be, e.g., formulation constituents capable of causing expansion of the formulation into a foam on application of reduced pressure.
  • Foaming agents can be, e.g., small bubbles suspended in the formulation, which can expand on application of reduced pressure and/or constituents capable of generating gas bubbles in the formulation.
  • Foaming agents can be, e.g., gasses in solution, gas forming chemicals, readily boiling solvents, entrapped or suspended bubbles, injected bubbles, and/or the like.
  • Surfactants can be included in the formulations of the methods to provide, e.g., increased solubility to other formulation constituents, protection against surface tension induced denaturation of certain biomolecules during foaming, bubble stabilization, faster reconstitution, and/or the like.
  • the surfactants can be, e.g., suitable ionic or non-ionic detergents, Tween surfactants, Pluronic surfactants, and/or the like.
  • Buffers can be added to the formulations of the method, e.g., to provide a suitable stable pH to the formulations of the method and compositions of the invention.
  • Typical buffers of the invention include, e.g., potassium phosphate, sodium phosphate, sodium acetate, histidine, imidazole, sodium citrate, sodium succinate, ammonium bicarbonate, and/or a carbonate.
  • the buffers can be adjusted to the appropriate acid and salt forms to provide, e.g., pH stability in the range from about pH 4 to about pH 10.
  • amino acids such as arginine and methionine can be constituents of the formulation and compositions.
  • the amino acids can, e.g., act as zwitterions that block charged groups on processing surfaces and storage containers preventing nonspecific binding of bioactive materials.
  • the amino acids can increase the stability of compositions by, e.g., scavenging oxidation agents, scavenging deamidation agents, and stabilizing the conformations of proteins.
  • glycerol can be included in the formulations of the invention, e.g., to act as a polyol and/or plasticizer in the dried foam composition.
  • EDTA can be included in the composition, e.g., to scavenge metal ions that can initiate destructive free radical chemistries.
  • Formulations of the invention can be cooled before foam expansion, foam stabilization, freezing, and/or drying, to provide benefits, such as, e.g., stabilization of bioactivity, thickening of the formulation, enhanced penetration of formulation constituents through membranes, and/or freezing the formulation before lyophilization.
  • Cooling can be by any appropriate technique known in the art.
  • cooling can be by contact and conduction with refrigerated hardware, contact with streams of cold fluids, loss of latent heat, and/or the like.
  • formulations are held in glass containers on metal racks within a temperature controlled process chamber where they equilibrate to the controlled temperature.
  • the chamber can include, e.g., pressure control capabilities so that cooling can be driven by loss of latent heat from evaporation or sublimation of formulation solvents.
  • the formulations of the invention can be, e.g., precooled to the phase transition temperature of biological material associated lipid membranes to enhance the penetration of protective agents.
  • the lipid bilayers of biological membranes, and monolayers of some liposomes can exist in a fluid phase at temperatures above the main phase transition temperature (T m ) and as a crystalline phase at temperatures below the T m .
  • Fluid phase membranes and crystalline phase membranes can present a continuous hydrophobic barrier to penetration by hydrophilic molecules. Without being bound to any particular theory, it is believed that at temperatures near the T m , transmembrane defects can exist at the boundaries between regions of fluid and crystalline phases on a lipid membrane.
  • transmembrane defects can provide increased permeability to hydrophilic molecules, such as many protective agents of the invention.
  • the formulation has a high solids content, a chemical gradient is produced which further drives the solutes, such as protective agents, into the membrane.
  • the protective agents can be retained within the membrane enclosed volume at stabilizing levels.
  • Enhanced process stability and storage stability for virus exposed to protective agents at the membrane phase transition temperature are shown in figures 4 and 5, respectively.
  • T m of many lipid membranes is above the freezing temperature and the glass transition temperatures (T g ) of formulations of the invention. This allows ready diffusion of protective agents in liquid solution through lipid membranes at about their T m .
  • T g glass transition temperatures
  • a 40% solution of sucrose remains liquid for effective penetration of a cell at a typical membrane T m of 15°C.
  • Increased permeability of protective agents in liquid solution through membranes in phase transition can protect biologic molecules within membrane enclosed volumes.
  • the T m of a membrane can be determined, e.g., Fourier Transformed
  • formulations of bioactive materials with lipid membranes can be held, e.g., at temperatures between about 0°C to about 70 0 C, about 2 0 C to about 45°C, about 12°C to 16°C, or about 15°C.
  • Live influenza virus foam dried at the putative phase transition temperature of 15° C was found to be more resistant to process-related potency loss (see, Figure 4) and exhibited significantly better long term stability at room temperature than that foam dried at 10° C and 20° C (see, Figure 5).
  • Formulations can be held at the T n , to allow adequate penetration of protective agents.
  • formulations can be held at the lipid membrane T m for about 10 to about 60 minutes, or about 30 minutes.
  • Foaming can result, e.g., from entrapment of gases released from the formulation and/or expansion of preexisting bubbles in suspension.
  • the boiling point of solvent constituents can drop below the temperature of the formulation, resulting in rapid evaporation or boiling of the solvent.
  • Significant bubbling can also occur in the formulation, e.g., when the pressure is reduced below the partial pressure of gasses dissolved in the solvent, resulting in bubbles from degassing.
  • Bubble formation can be chemically induced.
  • bubbling can be physically induced by introducing a gas through the bottom of the vessel, e.g., such as through fritted glass.
  • Expanding the formulation into a foam can be by, e.g., expansion of bubbles within the formulation by reduction of applied pressure.
  • the bubbles can be, e.g., preexisting, injected, and/or generated in situ.
  • the bubbles can be, e.g., suspended within the formulation before expansion, injected into the formulation before or during expansion, or generated by boiling, degassing, or gas forming chemical reactions.
  • Formulation constituents, e.g., included to promote expansion of the formulation into a foam can be foaming agents of the invention.
  • Expansion of the formulation can result, e.g., from boiling of the formulation. Boiling occurs, e.g., at the boiling point of a solvent, or when the vapor pressure of a formulation solvent exceeds the surrounding pressure. Boiling can be controlled, e.g., by adjusting the temperature of the formulation (higher temperatures result in higher vapor pressures) and/or by adjusting the applied pressure. Typically, formulations of the invention can be boiled under a reduced pressure (vacuum, or pressure less than atmospheric) to provide a lowered boiling temperature more conducive to the stability of bioactive materials. Formulations comprising a solvent with a low boiling point (or high vapor pressure) can boil at lower temperatures. For example, inclusion of certain alcohols, ethers, fluorocarbons, and/or the like, can provide lowered boiling points for formulations of the invention.
  • Degassing can, e.g., provide expansion of the formulation into a foam.
  • Gases can diffuse and dissolve into liquid solvents until an equilibrium is established between the partial pressures of gases in the liquid and the surrounding atmosphere. If the pressure of the surrounding atmosphere is, e.g., suddenly dropped, the gasses can rapidly escape the liquid as bubbles. For example, when an aqueous solution, which has been equilibrated with a gas at atmospheric pressure, is exposed to a lowered pressure, gas bubbles can form on the walls of the container or can erupt from the solution as a "fizz". This is not boiling, but is the release of dissolved gasses from the solution, or degassing. If the pressure is lowered further, the gasses can be substantially removed from the solution. Eventually, depending on the solvent, temperature and pressure, the solvent of the solution can begin to boil.
  • Formulations of the invention can be expanded into foams under reduced pressure by degassing.
  • Formulations can be exposed to gasses at suitable pressures, such as about one atmosphere (about 760 Torr at sea level) to about 500 atmospheres, to drive gasses into the formulation.
  • suitable pressures such as about one atmosphere (about 760 Torr at sea level) to about 500 atmospheres, to drive gasses into the formulation.
  • the reduced pressure providing expansion does not have to be a vacuum (less than 1 atmosphere).
  • the reduced pressure initiating expansion of bubbles can be, e.g., a vacuum.
  • Gasses that can act as foaming agents of the invention can be any known in the art, such as, air, nitric oxide, nitrogen, oxygen, low molecular weight hydrocarbons, inert gases, carbon dioxide, and/or the like.
  • Chemical reactions e.g., which generate a gas can provide expansion of the formulation into a foam.
  • Foaming agents of the invention can be, e.g., chemicals involved in gas generating chemical reactions, as will be appreciated by those skilled in the art.
  • a carbonate in the formulation can react with an acid to produce CO 2 gas.
  • active metals such as sodium or lithium
  • Electrolytic reactions using direct electric currents can be used, e.g., to provide hydrogen and/or oxygen gasses at electrodes.
  • Gasses generated within the formulation can, e.g., expand adiabatically or under constant pressure to expand the formulation into a foam.
  • gasses chemically generated within the formulation can be expanded by reduction of the applied pressure to expand the formulation into a foam.
  • Bubbles can be incorporated in to formulations, e.g., through mechanical processes.
  • Formulations can be expanded into foam, e.g., by forceful incorporation of gas bubbles into the formulation and/or by expansion of injected small bubbles in a reduced pressure.
  • bubbles can be stirred, whipped, homogenized, blown, jetted, agitated, sonicated, vortexed, blended, and/or the like, into the formulation.
  • the bubbles After introduction, e.g., into viscous formulations of the invention the bubbles can remain suspended in a matrix structure for extended periods of time. Suspended bubbles can be, e.g., expanded by application of reduced pressure and/or stabilized by drying or cooling of the formulation.
  • small bubbles e.g., 0.01 to 0.1 to 1 mm diameter
  • Foaming can be initiated or expanded by reducing pressure over the formulation. Foaming can be the result, e.g., from degassing of gasses from the formulation, expansion of small incorporated bubbles and/or boiling of the solvent. The escaping gasses can be trapped, e.g., by the viscous protective agents and/or surfactants of the formulation.
  • the foaming step can result in, e.g., initial drying of the formulation, thickening and structural stabilization, and/or freezing of the foam.
  • Processes for preservation of bioactive materials comprising lipid membranes includes, e.g., a combination of pre-cooling to a phase transition temperature and vacuum conditions that can result in freezing of the formulation. Because freezing can be a major cause of protein (and membrane damage) during freeze-drying, the prior art teaches the use of higher pressures (e.g., -100 Torr or more), concentrated solutions, and/or higher initial temperatures to prevent freezing.
  • higher pressures e.g., -100 Torr or more
  • concentrated solutions e.g., -100 Torr or more
  • the use of formulations containing various cryoprotective agents and process parameters of the invention can cryoprotect bioactive proteins and/or membranes should freezing result during the foam expansion, foam stabilization, or drying stages of the process.
  • Evaporation of solvent from the formulation can provide accelerated initial drying of the formulation under vacuum.
  • the boiling of solvent speeds initial drying of the formulation, e.g., by rapid transfer of solvent out of the formulation, convective turn over of the formulation, and by increasing the surface area. In many cases, it is desirable not to boil the formulation because the bubbles may be too large or the formulation may spill from containment.
  • the foam structure can be stabilized.
  • the protective agents in solution can become concentrated and thicker. Evaporation of solvent and loss of latent heat can cool the formulation. At some point, the cooled and concentrated protective agents can reach their glass transition temperature and stop flowing as a liquid. Loss of latent heat can result in freezing of the formulation. Typically, freezing can result from heat removal through contact with chilled surfaces and/or chilled atmosphere.
  • the glassy and/or frozen formulation can preserve a stable foam structure.
  • An open cell foam structure can be provided throughout, e.g., by providing an etched glass bottom to the holding container to promote bubble formation at the bottom of the container. Bubbles traveling up through the thickening formulation can form interconnected spaces of an open cell foam. Open cell foam can also be promoted by rapid drying and thickening that prevents settling of bubble free formulation or formation of a sealing skin over the formulation. Open cell foam can shorten secondary drying times and reconstitution times.
  • Foaming can be affected by conditions, such as, e.g., types and concentrations of formulation constituents, formulation temperatures, applied pressure levels, the rate of pressure changes, and/or the like.
  • conditions such as, e.g., types and concentrations of formulation constituents, formulation temperatures, applied pressure levels, the rate of pressure changes, and/or the like.
  • the presence of surfactants or thickening agents can stabilize bubbles for a less dense foam.
  • replacement of lost latent heat e.g., by heating the process chamber, can prolong the boiling of solvent.
  • lower pressures can provide more vigorous or continuous boiling and/or expansion.
  • Pressure can be reduced, e.g., to less than about 400 Torr, about 200 Torr or less, between about 100 Torr and about 25 Torr or less, between 25 Torr and 7.7 Torr or less, or between 2500 mTorr and about 50 mTorr, or about 25 mTorr or less, to produce desired foaming and/or freezing in the methods of the invention.
  • the vacuum can be maintained for about 1 hour or about 2 hours, e.g., to complete foaming, foam stabilization, and initial drying of the foam.
  • Initial (e.g., primary) drying in the methods of the invention can include, e.g., lyophilization.
  • latent heat is lost without replacement or heat is conducted away, e.g., the freezing temperature of the formulation can be reached.
  • the formulation can freeze, e.g., stabilizing a foam structure.
  • Initial drying can continue, e.g., as additional solvent is removed by sublimation into the vacuum.
  • the sublimation and/or evaporation can be driven, e.g., by removal of solvent (moisture) from the gaseous environment around the foam by condensation or desiccation.
  • Secondary drying of the structurally stabilized and initially dried foam can, e.g., remove entrapped solvent, or water of molecular hydration, to provide a composition that is stable in storage, e.g., for extended periods at ambient temperatures. Secondary drying can involve, e.g., application of cool to warm temperatures in a strong vacuum for several hours to days. In preferred embodiments for protection of bioactive materials comprising a life form, viability has been found to inordinately depend on temperature moderation, e.g., at or below room temperature during the secondary drying step.
  • heat can be added to the initially dried foam to drive off residual solvent.
  • heat can be added sparingly, e.g., to replace latent heat of evaporation or sublimation, without adding substantial amounts of additional heat, or raising the temperature of the foam.
  • Heat can be applied, e.g., through heating the reduced pressure atmosphere, as IR light, and/or heat can be conducted to the foam through associated hardware, such as shelves, trays, and glass vials.
  • the drying temperature can be, e.g., less than the glass transition temperature of the remaining composition in order to prevent collapse of the foam structure.
  • the methods of the invention result in a pharmaceutically-acceptable, glassy matrix comprising at least one biologically active material within the amorphous glassy matrix.
  • the glassy matrix can be a solid material forming the larger scale foam matrix structure of walls around hollow foam bubble cells.
  • the composition is almost completely dry. Some water or other aqueous solvent can remain in the composition but typically, not more than 10% residual moisture remains by weight.
  • the drying temperature can range from about 10°C to about 70°C, about 25°C to about 45°C, or about 35°C.
  • a typical secondary drying process for many bioactive materials can include, e.g., raising the temperature to a drying temperature of from about 30°C to about 35 0 C, and holding for from about 0.5 days to about 5 days to provide a stable dried foam composition with 0.1% to about 10%, or about 3% residual moisture.
  • the secondary drying temperature is less than 30 0 C, more preferably 25°C, 20 0 C or less.
  • the drying temperature is slowly raised from primary drying conditions in a slowly and continuously (e.g., with a temperature gradient profile) or in a series of small steps.
  • dry encompass those compositions with from about 0% to about 5% water.
  • the glassy matrix will have a moisture content from about 0.1% to about 3% as measured using the Karl Fisher method.
  • a vacuum can be provided in the secondary drying process to drive the rate of water removal and/or to push removal to lower residual moisture levels.
  • the vacuum during secondary drying can be, e.g., less than 400 Torr, less than 100 Torr, less than 2.5 Torr, less than 500 mTorr, less than 100 mTorr, less than 50 mTorr, or preferably about 25 mTorr.
  • relatively low pressures are employed in the secondary drying, e.g., less than 10 Torr, less than 1 Torr, less than 500 mTorr, less than 100 mTorr, less than 50 mTorr, thus speeding drying at the lower temperatures employed.
  • the resulting product from the freeze-foam drying process is generally an amorphous solid (see, Figure 8), wherein the glassy excipient material, e.g. sucrose, is in an amorphous glassy state and encases the biologically active material, thereby preventing protein unfolding and significantly slowing molecular interactions or cross-reactivity, due to greatly reduced mobility of the compound and other molecules within the glassy composition.
  • This process has been postulated to occur either via mechanical immobilization of the protein by the amorphous glass or via hydrogen bonding to polar and charged groups on the protein, i.e. via water replacement, thereby preventing drying induced denaturation and inhibiting further degradative interactions.
  • the labile proteins and/or bioactive material containing lipid membranes can remain relatively stable. It should be noted that achieving a glassy state is not necessarily a prerequisite for long term stability as some active ingredients may fare better in a more crystalline state. While it is generally recognized that biomaterials are generally easier to stabilize when dried to an amorphous glassy state, there are cases where the such glassy states are neither necessary nor sufficient for long term preservation. It is important to note that the mechanisms attributed to stabilization of biologicals can be multifactorial and not limited to the amorphous nature of the powder matrix in which the active ingredient is encased.
  • Stabilization under the process described here can involve a number of factors including but not limited to the reduction in conformational mobility and flexibility of the protein side chains and/or reduction in the free volume as a result of the encasement, improvement in the structural rigidity of the matrix, physical penetration of stabilizing agents, reduction in the phase separation of excipient from the active ingredient, improvement in the degree of water displacement by selecting the optimal hydrogen bonding donor.
  • the latter is a function of the affinity and avidity of the excipient for the surface of the protein, nucleic acids, carbohydrate, or lipids being stabilized. In general, as long as the solid is at a temperature below its glass transition temperature and the residual moisture remaining in the excipients is relatively low, the labile proteins and/or bioactive material containing lipid membranes can remain relatively stable.
  • Formulations can be, e.g., filled into containers before foaming and drying, or aliquoted into individual containers for use, as desired.
  • Formulations can be filled, e.g., into standard glass lyophilization vials for processing into stabilized foams.
  • the glass vials can be sterile with an etched bottom and a hermetically sealable stopper.
  • Bioactive materials of the invention can be administered, e.g., by injection of reconstituted solutions or suspensions, or inhalation of ground foam powder particles.
  • compositions described herein can be stable, i.e., they preserve the biological activity of the encased biologically active material and are chemically and/or physically stable.
  • the compositions were tested for stability by subjecting them to aging at elevated temperature (e.g., 37°C) and measuring the biological activity, chemical and/or physical stability of the formulations.
  • elevated temperature e.g. 37°C
  • results of these studies demonstrate that the virus formulated in these formulations were stable for at least one month at 50 0 C and for more than three months at 37°C (see, Figure 6). Stability is defined as time for one log fluorescent focus unit/ml (FFU/ml) potency loss.
  • the live influenza viruses were stabile for more than one year (see, Figure 7).
  • Such formulations are stable even when high concentrations of the biologically active material are used.
  • these formulations are advantageous in that they may be shipped and stored at temperatures at or above room temperature for long periods of time.
  • the stable composition of the bioactive material in an amorphous glassy matrix (see, Figure 8) provided after drying can be further processed using methods known in the art.
  • the glass matrix is easily divisible by cutting, milling, or other dividing techniques.
  • Processes for grinding or pulverizing drugs are well known in the art.
  • a hammer mill, an impact mill known as Entoleter mill, a jet mill, a pin mill, a Wiley mill, or similar milling device can be used.
  • the preferred particle size is less than about 100 um to about 0.1 um, and preferably less than 50 um.
  • Particles less than about 10 um in size are suitable, e.g., for pulmonary administration by inhalation, while larger particles can be suitable for administration to the upper respiratory tract and nasal regions.
  • the particle size can be chosen so as to obtain varying dispersion and flowability characteristics. For example, free flowing powders may be especially desirable for intranasal or pulmonary delivery.
  • the powdered compositions of the invention can be easily rehydrated with water, saline, or other fluids.
  • Dry foam compositions can be reconstituted with a suitable aqueous buffer for administration by injection or inhalation.
  • compositions of the invention can be administered to a mammal by delivering the bioactive material through the intravenous, intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, intranasal, or pulmonary routes.
  • the large surface area of foam and the high solubility of many protective agents allows dry foams of the invention to be reconstituted at lower or higher concentrations than the original formulation.
  • the bioactive material can be reconstituted at high concentrations, such as up to about 400 mg/ml, for delivery of an adequate dose in a small volume subcutaneous injection. Less concentrated reconstituted solutions can be, e.g., administered as an aerosol by inhalation.
  • the choice of administration route can depend on, e.g., the site of action, pharmacological considerations, and the like.
  • a typical dose of a bioactive material in the methods of the invention is from about 0.01 ng/kg to about 15 mg/kg.
  • the appropriate dosage ("therapeutically effective amount") of the biologically active material will depend, for example, on the condition to be treated, the severity and course of the condition, whether the biologically active material is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the biologically active material, the type of biologically active material used, and the discretion of the attending physician.
  • the biologically active material can be suitably administered to the patent at one time, or over a series of treatments, and may be administered to the patent at any time from diagnosis onwards.
  • the biologically active material may be administered as the sole treatment or in conjunction with other drugs or therapies useful in treating the condition in question.
  • the therapeutically effective amount of the biologically active material administered will be in the range of about 0.01 ng/kg to about 50 mg/kg of patent body weight whether by one or more administrations, with the typical range of protein used being about 0.05 ng/kg to about 20 mg/kg, more preferably about 0.1 ng/kg to about 15 mg/kg, administered daily, for example.
  • other dosage regimens may be useful.
  • the progress of this therapy can be monitored by conventional techniques.
  • an article of manufacture comprising a container which holds the pharmaceutical compositions of the present invention and optionally provides instructions for its use. Suitable containers include, for example, bottles, vials and syringes.
  • the container may be formed from a variety of materials such as glass or plastic.
  • An exemplary container is a 3-20 cc single use glass vial.
  • the container may be 3-100 cc glass vial.
  • the container holds the formulation and the label on, or associated with, the container may indicate directions for use.
  • the article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
  • compositions of the invention include dry foam compositions of a bioactive material and a polyol and/or a polymer. Because the compositions were prepared by freezing before drying, they are inherently different in structure and function from foams that were dried without first freezing. For example, note the differences between merely drying a formulation and freeze drying a formulation, even at the macroscopic level. Compositions of the invention can be prepared, e.g., by the methods of the invention.
  • compositions of the invention can be prepared by, e.g., preparing a formulation of a polyol and a bioactive material with lipid membranes, cooling the formulation to a temperature of about a phase transition temperature of the lipid membranes, reducing pressure on the formulation to form a foam, freezing the foam, and sublimating water from the frozen foam to provide a lyophilized dry foam composition. Secondary drying conditions can be employed to further dry the foam.
  • Compositions of the invention include, e.g., reconstituted dry foam in an aqueous buffer.
  • the composition of the invention is a vaccine of live attenuated Influenza virus.
  • the composition is prepared, e.g., according to the methods of the invention including secondary drying the foam at a drying temperature below the glass transition, e.g., between 20°C and 35 0 C, for between 6 hours and 5 days, to provide a final composition with less than about 5% residual moisture.
  • a drying temperature below the glass transition e.g., between 20°C and 35 0 C
  • Such a composition can remain stable in storage at about 25°C for 1 year or more.
  • Initial viability through the process can be substantially improved by holding the virus in the formulation at a temperature near the membrane phase transition temperature (e.g., about 15°C; see Figure 4) and/or secondary drying at a relatively low temperature (e.g., 22°C).
  • compositions can be prepared of a bioactive material in a foam with less than 10 percent residual moisture while retaining high levels of viability.
  • a bacteria in the Enterobactereacea family can be formulated with a polyol and/or polymer, exposed to a vacuum to generate a foam, frozen and lyophilized, secondarily dried at a temperature ramped up to about 25°C (or less) over the course of hours or days, to produce a composition that retains 25 percent, 50 percent, 75 percent, 90 percent or more of the viable colony counts found in the initial liquid formulation.
  • Figures 5 and 6 show charts of stability data for an envelope virus preserved in the dry foam of the invention and stored at 25°C, 37°C, and 50 0 C.
  • the charts of potency fluorescent focus units per mL - FFU/mL
  • Trend lines 51 and 95% confidence intervals 52 indicate a predicted stability (not more than 1 log potency loss) of about 40 months for virus stored in the composition of the invention at 25°C.
  • compositions of the invention include, e.g., blood platelets preserved in stable storage as bioactive material in a dry foam.
  • Blood platelets are cytoplasmic fragments from megakaryocytes that can aggregate at the site of blood vessel lesions to prevent bleeding and initiate repairs.
  • Platelet infusions into patients are used to correct deficiencies or dysfunctions of circulating platelets as a result of trauma, disease, or drug induced dysfunction. For example, patients suffering from idiopathic thrombocytopenia, sickle cell anemia, and those undergoing ablative chemotherapy can be treated with platelet infusions. The increasing use of ablative chemotherapy for a wide variety of malignancies has resulted in an increased need for replacement platelet therapy.
  • Platelets are only approved by the Food and Drug Administration (FDA) for storage in a liquid state for up to five days at room temperature, during which time the functional properties rapidly deteriorate. This causes many logistic problems in both civilian and military medicine.
  • FDA Food and Drug Administration
  • compositions for preservation of platelets can be prepared by collecting blood into a suitable anticoagulant followed by obtaining platelet rich plasma (PRP) by any method known in the art.
  • PRP platelet rich plasma
  • the platelets can be processed according to the methods of the invention to yield a stable dried foam comprising the platelets. Because platelets are large and more complex structure than a virus, drying at its characteristic phase transition is particularly important.
  • the dried platelets can be reconstituted by resuspension in a physiologically acceptable buffer before infusion.
  • the buffer is sterile.
  • the buffer can be any buffer of suitable pH.
  • the reconstitution buffer can contain a substance or substances that exhibit high colloidal osmotic pressure, including, but not limited to, polyethylene glycol (PEG) and hydroxy-ethyl starch (HES).
  • PEG polyethylene glycol
  • HES hydroxy-ethyl starch
  • the buffer is 1-5% human serum albumin (HSA) in saline.
  • HSA human serum albumin
  • platelets, liposomes, animal cells and plant cells care treated as recommended for other microbes, e.g., using membrane phase transition temperature infusion of protectants and using low temperature/high vacuum secondary drying.
  • Formulations for preparation of dry foam compositions of the invention can include, e.g., polymers, polyols, foaming agents, surfactants, and/or buffers. Such formulations can be processed according to methods of the invention to provide stable compositions for storage and administration of the bioactive materials.
  • Bioactive materials of the invention include, e.g., materials with detectable bioactivity in living systems, biological cells and molecules used in analysis, biological cells and molecules used in medicine, biological cells and molecules used in research, and/or the like.
  • bioactive materials of the compositions of the invention include peptides, proteins, hormones, nucleic acids, antibodies, vaccines, bacteria, viruses, liposomes, platelets, cell suspensions, and/or the like.
  • Bioactive materials comprising lipid membranes in the compositions are generally live, and/or attenuated, biologically active, viable or non-living, cells, viruses, microorganisms (such as, for example, bacteria), and/or liposomes.
  • bioactive agents can include vaccines, viruses, liposomes, bacteria, platelets, and/or cells.
  • Viral bioactive agents can include, e.g., influenza virus, parainfluenza virus, AAV, adenovirus, respiratory syncytial virus, herpes simplex virus, SARS virus, human metapnuemovirus, corona virus family members, cytomegalovirus, and/or Epstein-Barr virus which can be present in the formulations of the invention in amounts ranging from about 10 1 TCID 5 o/mL or more, from about 10 3 TCJD 50 ZmL up to about 10 12 TCTD 50 ImL, or from about 10 6 TCIDso/mL to about 10 9 TCIDso/mL.
  • the bioactive material will generally be present in an amount of less than about 1%; more preferably, less than about 0.001%; and most preferably, less than about 0.0001% by weight.
  • the formulations for preparation of dry foam compositions can include, e.g., substantial total solids (constituents minus the solvent, such as water).
  • a major portion of the total solids can comprise the bioactive material, a polyol, and/or a polymer.
  • the polyol can be present in the formulation in a concentration ranging from about 2 weight percent to about 50 weight percent, from about 5 weight percent to about 45 weight percent, or from about 20 weight percent to about 40 weight percent.
  • the polymer can be present in the formulation in a concentration ranging from about 1 weight percent to about 10 weight percent, or about 5 weight percent.
  • the formulation should have a high solids content before initiation of foaming; typically between about 5% and 70%, or between about 30% to 50%.
  • the viscosity of formulations of the invention are typically greater than 5 centipoise (cP); more preferably, greater than 10 cP.
  • a preferred formulation exhibits -12 cP.
  • Polyols of the invention can include, e.g., various sugars, carbohydrates, and alcohols.
  • the polyols can include non-reducing sugars, sucrose, trehalose, sorbose, melezitose, and/or raffinose.
  • the polyols can include, e.g., mannose, maltose, lactose, arabinose, xylose, ribose, rhamnose, galactose and glucose, mannitol, xylitol, erythritol, threitol, sorbitol, glycerol, or L-gluconate.
  • the polyol is preferably one which does not crystallize at freezing temperatures (e.g. -2O 0 C) such that it destabilizes the biologically active material in the formulation. It can be beneficial to include two or more different polyols to inhibit formation of crystals.
  • Polymers of the invention can include, e.g., various carbohydrates, polypeptides, linear and branched chain hydrophilic molecules.
  • polymers of the formulation can include gelatin, hydrolyzed gelatin, ovalbumin, polyvinylpyrrolidone, collagen, chondroitin sulfate, a sialated polysaccharide, actin, myosin, microtubules, dynein, kinetin, or human serum albumin.
  • These additives do not necessarily solely stabilize the biologically active material against inactivation; they also may help to prevent the physical collapse of the freeze-dried material during lyophilization and subsequent storage in the solid state.
  • Other gelatin substitutes that may also function as stabilizers include native collagen and alginate.
  • gelatin and more preferably, hydrolyzed gelatin, is used.
  • Hydrolyzed gelatin refers to gelatin that has been subjected to partial hydrolysis to yield a partially hydrolyzed gelatin having a molecular weight of from about 1 kDa to about 50 kDa, or about 3 kDa.
  • This gelatin hydrolysis product has approximately the same amino acid composition as gelatin.
  • the typical amino acid composition of hydrolyzed gelatin is known.
  • Partially hydrolyzed gelatin may be obtained from any number of commercial sources.
  • Partially hydrolyzed gelatin may also be obtained by enzymatic hydrolysis of gelatin by means of a proteolytic enzyme, such as, for example, papain, chymopapain, and bromelin, although other known hydrolysis means may be employed, e.g., acid hydrolysis.
  • a gelatin having a molecular weight of between about 1 kDa and 50 kDa is used.
  • Gelatin hydrolyzed to about 3 kDa or less can be less allergenic than full length gelatin.
  • the gelatin may be derived from a variety of sources, including pig and bovine.
  • Humanized collagen as well as highly processed collagen for example, FreAlagin, a pharmaceutical gelatin with reduced allergenicity, available from Miyagi Chemical Industrial Co, Ltd., can be used.
  • the amount of gelatin used in the formulation will vary depending on the overall composition of the formulation and its intended use. Generally, the concentration of gelatin will be from about 1 to about 7%; more preferably, between about 1 and 5%.
  • a preferred formulation comprises about 5% gelatin.
  • Formulations for preparation of the compositions of the invention can include, e.g., one or more surfactants to aid in solubility and stability of formulation constituents; and to help form and stabilize foam.
  • the surfactants can include, e.g., nonionic detergents, such as polyethylene glycol sorbitan monolaurate (Tween 20), polyoxyethylenesorbitan monooleate (Tween 80), block copolymers of polyethylene and polypropylene glycol (Pluronic), and/or the like.
  • the formulations can include ionic detergents.
  • Formulations and compositions of the invention can include surfactants, such as, e.g., polyethylene glycol, polypropylene glycol, polyethylene glycol/polypropylene glycol block copolymers, polyethylene glycol alkyl ethers, polypropylene glycol alkyl ethers, polyethylene glycol/polypropylene glycol ether block copolymers, alkylarylsulfonates, phenylsulfonates, alkyl sulfates, alkyl sulfonates, alkyl ether sulfates, alkyl aryl ether sulfates, alkyl polyglycol ether phosphates, polyaryl phenyl ether phosphates, alkylsulfosuccinates, olefin sulfonates, paraffin sulfonates, petroleum sulfonates, taurides, sarcosides, fatty acids, alkylnaphthalenes
  • Buffers can be present, e.g., to control pH, enhance stability, affect constituent solubility, provide comfort on administration, and the like, in formulations for preparation of dry foam compositions.
  • Formulation pH can be controlled in the range of about pH 4 to about pH 10, from about pH 6 to about pH 8, or about pH 7.2.
  • Preferred buffers are often paired acid and salt forms of a buffer anion generally recognized as safe for the particular route of administration of the bioactive material.
  • Typical buffers for use in the formulations and compositions of the invention include, e.g., potassium phosphate, sodium phosphate, sodium acetate, sodium citrate, histidine, imidazole, sodium, succinate, ammonium bicarbonate, carbonates, and the like.
  • the formulation contains the above-identified agents
  • a preservative may be included in the formulation, particularly when the formulation is a multidose formulation.
  • One or more pharmaceutically acceptable carriers, excipients, or stabilizers such as those described in Remington's Pharmaceutical Sciences 16 th Edition, Osol, A. Ed. (1980) may be included in the formulation provided that they do not adversely affect the desired characteristics of the formulation.
  • Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed and include; additional buffering agents; co-solvents; salt-forming counterions such as potassium and sodium; antioxidants, such as methionine, N-acteyl cysteine, or ascorbic acid; chelating agents, such as EDTA or EGTA.
  • Amino acids, such as, e.g., arginine and methionine can be included in the formulations.
  • Arginine can be present in the formulations in an amount ranging from about 0.1 weight percent to about 5 weight percent.
  • Methionine can be present in the formulation in a concentration ranging from about 1 mM to about 50 mM or about 10 mM.
  • Glycerol can be present in the formulation in a concentration ranging, e.g., from about 0.1 weight percent to about 5 weight percent, or about 1 weight percent.
  • EDTA can be present in the formulation in a concentration ranging, e.g., from about 1 mM to about 10 mM, or about 5 mM.
  • This example describes a composition that maintained protein integrity and stability after storage at 37 0 C for 125 days.
  • Monovalent live attenuated influenza virusB/Harbin(CAZ039 lot) was formulated as an 8.0 log FFU/ml titer solution (-10 microgram/ml total protein concentration of viral stock solution) containing 40% sucrose, 5% gelatin, 0.02% Pluronic F68, 25 mM 7.2 pH KPO 4 buffer.
  • One mL aliquots of this solution were then dispensed into 10 mL glass lyophilization vials, partially covered with lyophilization stoppers, and lyophilized using a VirTis Genesis 25EL lyophilizer (available from VirTis, Gardiner, NY) according to the following cycle conditions:
  • the resultant foam had a moisture content of approximately 2.2% (w/w) and a T g of about
  • thermostability of the above formulations after post-lyophilization storage at 37°C or 50°C were measured. Increased thermostability can be observed as shown as a decrease in the rate of potency loss, measured as the log FFU/ml or TCED 5 o/ml.
  • the time required for a one log order loss in FFU/ml are provided below for various formulations of the invention:
  • FIG. 9 shows a chart of vial temperatures verses sucrose mass fraction (dryness level) throughout the process. Vials of a Listeria formulation were placed into a pressure and temperature controlled chamber. The process started 80 with the Listeria in a formulation of about 30% sucrose at 15°C. The formulation was expanded to produce a foam in a foaming step 81. The foam was then frozen 82 and water removed in a primary drying step at a shelf temperature of 15°C by evaporation and sublimation 83.
  • the secondary drying step 84 was accelerated by raising the chamber temperature rapidly to about 33°C, as for our standard non-foamed lyophilization. Secondary drying continued until residual moisture was about 3% 85. Samples were taken at various points during the process for Listeria colony counts.
  • freeze-foam drying and standard lyophilization processes were the foaming and convective boil drying that occurs before freezing, and the extended secondary drying time involved in the freeze-foam process. These experiments provided a surprise result that these factors are not the major contributors to viability losses observed in comparisons of freeze foam and standard lyophilization processes. This experiment identified one variable among many that has a predominant influence on viability outcome. By reducing secondary drying temperatures for freeze-foam drying, we have found that comparable viabilities can be obtained as for standard lyophilization.
  • freeze-foam preservation processes can benefit from providing lower temperatures during secondary drying steps. However, this can lead to longer processing times that can affect manufacturing productivity.
  • the following examples identify systems elements that could speed up low temperature secondary drying used in certain freeze-foam drying process of the invention.
  • the surface to volume ratio for freeze foam dried materials can be relatively low compared to, e.g., many lyophilization or spray dry processes. This disadvantage can be particularly problematic when a deep or thick frozen foam is to be dried in a substantially enclosed container, such as a lyophilization vial. We believe secondary drying at low secondary drying temperatures can be accomplished at practical time scales and resulting in high viability for viruses and microorganisms, e.g., by reducing container interference with drying and/or by reducing the distance water must travel to exit the foam.
  • Systems can be designed to speed low temperature drying of frozen foams.
  • systems can include an environment control chamber 110, e.g., providing control of internal temperatures and pressures.
  • a bioactive material formulation 111 liquid solution and/or suspension
  • the formulation can be disposed upon a surface 112.
  • the surface can be the inner surface of a container, for more rapid drying it is preferably not an inner surface of a container.
  • the internal pressure of the chamber can be reduced to expand the formulation into a foam 113.
  • the foam can be frozen, e.g., by exposure to a chilled internal atmosphere, evaporative cooling, and/or chilling of the surface 112.
  • the frozen foam has a thickness 114 less than about 10 mm, less than 5 mm, less than 2 mm, about 1 mm or less.
  • the thin foam directly exposed to the inner chamber environment without interference from a container, can progress rapidly through secondary drying to 10% residual moisture or less.
  • frozen foam can be lyophilized and secondarily dried in either batch or continuous mode, e.g., on the surface of a large container, a plate, a belt, or a drum 115.
  • formulation can be applied by spraying a layer onto a drum surface.
  • the layer can be expanded to a foam layer by an internal vacuum.
  • the foam can be frozen onto the surface with primary drying can be by lyophilization.
  • the drum can rotate and transfer heat into or out of the layer as desired, at different points along the rotation, e.g., by contact with heat exchangers, temperature controlled gas streams, infrared light, thermoelectric devices and/or the like.
  • the drum surface can be chilled to freeze the foam.
  • the surface can then be heated slightly at points further along positions of drum rotation to replace heat lost by sublimation.
  • additional heat can be applied to the surface to maintain, e.g., about 25°C to remove residual moisture.
  • freeze-foam dried bioactive material product can be harvested from the drum, e.g., by scrapping.
  • foaming, freezing, primary drying, secondary drying and harvest can occur in a batch sequence process on the entire process surface.
  • formulation can be poured or spread onto a plate or the bottom of a large open mouth container to form a thin layer.
  • the sheet can be placed into an environmental control chamber and the formulation can be expanded to a thin foam (e.g., 1 mm to 10 mm) by a pressure reduction.
  • the foam can be frozen by a combination of latent heat loss and heat conduction out of the foam.
  • Primary drying can be by sublimation with latent heat replaced from the surrounding atmosphere of the temperature controlled chamber.
  • Secondary drying can include exposure of the foam to an atmosphere at 15-25°C for a time necessary to obtain 5% relative humidity.
  • the foam can be harvested by breaking the foam sheet into particles and pouring them into conventional containers for storage.
  • Listeria was freeze-foam dried in a formulation of sucrose (pure Tg 34.5°C) and in a formulation of trehalose (pure Tg 53.9). The formulations were dried in vials at temperatures that passed above the Tg of the sucrose formulation but remained below the Tg of the trehalose formulation. As shown in the chart of Figure 14, the viability of the Listeria through the process steps and in the final dried product was not appreciably influenced by whether or not the matrix remained in a glassy state during the drying process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés, des systèmes et des compositions permettant de conserver des substances biologiquement actives dans une matrice de mousse déshydratée. Les procédés concernent la production d'une mousse sans ébullition et la pénétration d'agents conservateurs à des températures proches de la température de transition de phase des membranes. Les substances biologiquement actives peuvent être conservées avec une viabilité initiale élevée dans un processus de lyophilisation de mousse utilisant une dessiccation secondaire à faible température.
PCT/US2008/005840 2007-05-18 2008-05-06 Conservation de substances biologiquement actives par mousse lyophilisée WO2008143782A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK08767620.1T DK2148923T3 (da) 2007-05-18 2008-05-06 Konservering af biologisk aktive materialer med frysetørret skum
US12/451,454 US8617576B2 (en) 2007-05-18 2008-05-06 Preservation of bioactive materials by freeze dried foam
JP2010509335A JP5307801B2 (ja) 2007-05-18 2008-05-06 凍結乾燥フォームによる生物活性材料の防腐
BRPI0811161-8A2A BRPI0811161A2 (pt) 2007-05-18 2008-05-06 Conservação de materiais bioativos por espuma liofilizada.
ES08767620T ES2393160T3 (es) 2007-05-18 2008-05-06 Conservación de materiales bioactivos con espuma liofilizada
CN200880025155.3A CN101755044B (zh) 2007-05-18 2008-05-06 通过冻干泡沫保存生物活性材料
EP08767620A EP2148923B1 (fr) 2007-05-18 2008-05-06 Conservation de substances biologiquement actives par mousse lyophilisée

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93074607P 2007-05-18 2007-05-18
US60/930,746 2007-05-18

Publications (1)

Publication Number Publication Date
WO2008143782A1 true WO2008143782A1 (fr) 2008-11-27

Family

ID=40122017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005840 WO2008143782A1 (fr) 2007-05-18 2008-05-06 Conservation de substances biologiquement actives par mousse lyophilisée

Country Status (9)

Country Link
US (1) US8617576B2 (fr)
EP (1) EP2148923B1 (fr)
JP (2) JP5307801B2 (fr)
KR (1) KR101557169B1 (fr)
CN (1) CN101755044B (fr)
BR (1) BRPI0811161A2 (fr)
DK (1) DK2148923T3 (fr)
ES (1) ES2393160T3 (fr)
WO (1) WO2008143782A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9827305B2 (en) 2014-02-17 2017-11-28 Intervet Inc. Poultry virus vaccines that are liquid stable
US9839613B2 (en) 2013-09-27 2017-12-12 Intervet Inc. Dry formulations of vaccines that are room temperature stable
US9855336B2 (en) 2014-02-19 2018-01-02 Intervet Inc. Swine virus vaccines that are liquid stable
EP3369805B1 (fr) 2015-10-30 2020-08-26 Kabushiki Kaisha Yakult Honsha Procédé de fabrication de cellules microbiennes séchées
US11639491B2 (en) * 2017-10-27 2023-05-02 Kumiai Chemical Industry Co., Ltd. Microorganism lyophilized composition
US11801218B2 (en) 2010-07-26 2023-10-31 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7077176B2 (en) 2003-04-28 2006-07-18 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP1973406B1 (fr) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation Véhicule de délivrance pour bactéries probiotiques, comprenant une matrice sèche en polysaccharides, saccharides et polyols sous forme de verre
JP5566101B2 (ja) 2006-04-24 2014-08-06 メディカル・インスティル・テクノロジーズ・インコーポレイテッド 針貫通可能かつレーザ再密閉可能な凍結乾燥装置およびこれに関連する方法
CA2673120C (fr) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
ES2908047T3 (es) 2009-03-27 2022-04-27 Intervet Int Bv Vacunas en micropartículas para la vacunación oral o nasal y el refuerzo de animales incluidos los peces
NZ597053A (en) 2009-05-26 2014-02-28 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
EP2529004B1 (fr) 2010-01-28 2017-06-07 Advanced Bionutrition Corporation Composition vitreuse sèche comprenant un matériau bioactif
EA027915B1 (ru) 2010-02-19 2017-09-29 Кадила Фармасьютикалз Лимитед Способ получения композиции убитых клеток, по существу, с сохраненной иммуногенностью
RU2573324C2 (ru) 2010-08-13 2016-01-20 Эдванст Байоньютришн Корпорейшн Стабилизирующая композиция для сухого хранения биологических материалов (варианты)
EP2841408A4 (fr) * 2012-04-22 2016-06-22 Cargill Inc Procédés de maintien et d'amélioration de la fonction et de l'activité biologiques cellulaires
US20140017318A1 (en) 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20140193456A1 (en) * 2013-01-09 2014-07-10 Hristem Mitkov Dyanov Method for Drying-Conservation of Natural Substances
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
EP3057978B1 (fr) 2013-10-16 2022-09-14 Merck Sharp & Dohme LLC Procédé de séchage sous vide aux micro-ondes de granules sphériques de matières biologiques
US10369213B2 (en) 2013-10-16 2019-08-06 Merck Sharp & Dohme Corp. Thermostable respiratory synctial virus (RSV) vaccine compositions
CA2927434C (fr) 2013-10-16 2022-07-19 Merck Sharp & Dohme Corp. Procede d'obtention de formulations de vaccin sechees thermostables
WO2017019273A1 (fr) 2015-07-29 2017-02-02 Advanced Bionutrition Corporation Compositions probiotiques sèches stables pour des utilisations diététiques
WO2018081550A1 (fr) 2016-10-28 2018-05-03 Vedanta Biosciences, Inc. Procédés et compositions pour la conservation de bactéries
TWI719220B (zh) * 2017-06-13 2021-02-21 英屬維爾京群島商大利緯眾生物科技股份有限公司 用於血清蛋白的活性保存的新穎方法
WO2018227359A1 (fr) * 2017-06-13 2018-12-20 Chung Chin Sun Nouveau procédé de préservation de l'activité des protéines du plasma sanguin
CA3069444A1 (fr) * 2017-07-11 2019-01-17 Universal Stabilization Technologies, Inc. Procede de conservation de produits biopharmaceutiques
AU2018336988B2 (en) * 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
KR102649069B1 (ko) * 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
WO2019231134A1 (fr) * 2018-05-31 2019-12-05 주식회사 엑소코바이오 Composition pour soulager les rougeurs du visage, comprenant des exosomes dérivés de cellules souches en tant que principe actif
JP7079984B2 (ja) 2018-07-28 2022-06-03 エクソコバイオ インコーポレイテッド エキソソームの凍結乾燥方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
US11243028B2 (en) * 2018-12-14 2022-02-08 Fortunata, LLC Systems and methods of cryo-curing
CN111214392B (zh) * 2020-01-08 2021-02-26 江苏悦智生物医药有限公司 一种球形化妆品冻干泡及其制备方法
KR20230038486A (ko) 2020-06-23 2023-03-20 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 호흡기 병원체를 진단하는 방법 및 covid-19 관련 결과를 예측하는 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423252B1 (en) * 2000-06-23 2002-07-23 Ethicon, Inc. Methods of making micropatterned foams
US20030219475A1 (en) * 2002-04-11 2003-11-27 Medlmmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
WO2005067460A2 (fr) 2003-12-24 2005-07-28 Medimmune, Inc. Vaccins epha2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
US6468782B1 (en) * 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6306345B1 (en) 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
US7094412B2 (en) * 2001-12-10 2006-08-22 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable poxvirus containing compositions
BR0315767A (pt) * 2002-11-01 2005-09-06 Glaxosmithkline Biolog Sa Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
CN100569286C (zh) * 2003-02-20 2009-12-16 森特拉·耐科奥诺·德·因威斯迪盖什斯·西恩蒂菲科斯(Cnic) 用于口服接种的冻干形式的具有改良的生物安全性特征的霍乱弧菌(Vibrio cholerae)减毒株
ZA200803526B (en) 2005-09-26 2009-10-28 Aeras Global Tb Vaccine Found Process for stabilization of bacterial cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423252B1 (en) * 2000-06-23 2002-07-23 Ethicon, Inc. Methods of making micropatterned foams
US20030219475A1 (en) * 2002-04-11 2003-11-27 Medlmmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
WO2005067460A2 (fr) 2003-12-24 2005-07-28 Medimmune, Inc. Vaccins epha2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. A. ANGELL: "Formation of from Liquids and Biopolymers", SCIENCE, vol. 267, 31 March 1995 (1995-03-31), pages 1924 - 1935
GIBBS: "Nature of the Glass Transition and the Glassy State", JOURNAL OF CHEMICAL PHYSICS, vol. 28, no. 3, March 1958 (1958-03-01), pages 373 - 383
JAN P. WOLANCZYK: "Differential Scanning Calorimetry Analysis of Glass Transitions", CRYO-LETTERS, vol. 10, 1989, pages 73 - 76
OSOL, A.: "Remington's Pharmaceutical Sciences,16th Edition,", 1980
See also references of EP2148923A4

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11801218B2 (en) 2010-07-26 2023-10-31 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
US9839613B2 (en) 2013-09-27 2017-12-12 Intervet Inc. Dry formulations of vaccines that are room temperature stable
US9827305B2 (en) 2014-02-17 2017-11-28 Intervet Inc. Poultry virus vaccines that are liquid stable
US9855336B2 (en) 2014-02-19 2018-01-02 Intervet Inc. Swine virus vaccines that are liquid stable
EP3369805B1 (fr) 2015-10-30 2020-08-26 Kabushiki Kaisha Yakult Honsha Procédé de fabrication de cellules microbiennes séchées
US11639491B2 (en) * 2017-10-27 2023-05-02 Kumiai Chemical Industry Co., Ltd. Microorganism lyophilized composition

Also Published As

Publication number Publication date
ES2393160T3 (es) 2012-12-19
CN101755044A (zh) 2010-06-23
CN101755044B (zh) 2014-06-11
JP5307801B2 (ja) 2013-10-02
JP2013177473A (ja) 2013-09-09
EP2148923A1 (fr) 2010-02-03
DK2148923T3 (da) 2012-12-03
BRPI0811161A2 (pt) 2014-10-07
KR20100028561A (ko) 2010-03-12
US20100297231A1 (en) 2010-11-25
EP2148923B1 (fr) 2012-08-22
KR101557169B1 (ko) 2015-10-02
JP2010528003A (ja) 2010-08-19
EP2148923A4 (fr) 2010-11-24
US8617576B2 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
US8617576B2 (en) Preservation of bioactive materials by freeze dried foam
US7381425B1 (en) Preservation of bioactive materials by freeze dried foam
EP1750760B1 (fr) Conservation par vaporisation
AU2012204056B2 (en) Preservation by vaporization

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880025155.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08767620

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008767620

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010509335

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7382/CHENP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20097026374

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12451454

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0811161

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091118